PSA Testing and Prostate Cancer Screening: Who Should Consider It, and When

Prostate cancer screening usually means a PSA blood test, and for most men it is offered as a shared decision, typically between the ages of 55 and 69, rather than as a routine test that everyone should simply have. I do not have a prostate, so this is the one screening topic I came to sideways, through my father, who was handed a PSA leaflet at 63 and asked me, reasonably, what on earth he was supposed to do with it. Sorting out an honest answer for him is why this article exists.

What prostate cancer screening actually is

PSA screening is a blood test that measures prostate-specific antigen, a protein made by the prostate; it does not diagnose cancer, it flags men who might need a closer look. Prostate cancer is one of the most commonly diagnosed cancers in men worldwide, which is exactly why the idea of catching it early is so appealing ¹. The catch is that a raised PSA and a cancer are not the same thing, and the whole difficulty of this subject lives in that gap.

This is the defining feature of any screen: it sorts people who feel perfectly well into those who need further assessment and those who do not, and a positive result is the start of a pathway, not the end of one. If that distinction feels abstract, it is worth reading how a screening test differs from a diagnostic test, because the entire PSA debate turns on treating the first as if it were the second.

Who should consider a PSA test, and when

For most men the question lands between about ages 55 and 69, where guideline bodies frame PSA testing as an individual decision rather than a blanket recommendation. The U.S. Preventive Services Task Force, for example, grades screening in this band as a C, meaning it should be offered selectively based on a man’s own circumstances and values, and recommends against routine PSA screening from age 70 onward, where the balance tips toward harm ². The band exists because that is roughly where the small potential benefit is at its largest relative to the costs.

Risk shifts the conversation earlier for some men. A father or brother diagnosed young, or certain ancestral backgrounds that carry higher baseline risk, can be reasons to have the discussion in your late 40s rather than your mid 50s. None of that makes testing automatic; it makes the conversation worth having sooner. My father, at 63, sat squarely inside the band where the honest answer is genuinely “it depends on what you want”, which is a frustrating thing to hear when you were hoping for a yes or a no.

What a PSA number actually means

There is no PSA level that cleanly rules cancer in or out, so a single number is far weaker evidence than most people expect. A threshold around 4 ng/mL is often used as the point that prompts a closer look, but the value climbs naturally with age and with a benign, enlarging prostate, and most men with a mildly raised PSA do not have cancer at all ². Infection, recent ejaculation, and even a hard bike ride the day before can nudge it up.

Because of that, a raised result is usually repeated rather than acted on immediately, to see whether it holds and which way it is trending. Reading one PSA reading as a verdict is the same mistake people make with any flagged blood value, and it produces the same needless fear. If a raised number does persist, the pathway can move on to an MRI and, where warranted, a biopsy, each step deciding whether the next one is justified.

What screening can genuinely prevent

The benefit of PSA screening is real but modest, and stating the size of it honestly is the only way to make a fair decision. In the largest European randomised trial, screening prevented roughly 1 prostate cancer death for every 1000 men invited over about 13 years ². That is a genuine life saved, and it is also a smaller number than the word “screening” tends to conjure. A pooled Cochrane analysis was more cautious still, finding that PSA screening did not significantly reduce deaths from any cause and produced only a marginal, uncertain effect on prostate cancer deaths specifically ³.

Two careful readings of the same evidence, then, land in slightly different places, which is itself the honest picture: a small benefit that is easy to overstate. This is the fuller context behind how cancer screening is judged and who it actually helps, where the same tension between a real but limited benefit and a measurable cost runs through almost every programme.

The harms: overdiagnosis and the follow-up chain

The main cost of PSA screening is overdiagnosis: finding cancers that are real under the microscope but would never have caused symptoms or shortened a man’s life. Estimates vary, but a substantial share of screen-detected prostate cancers, by some analyses in the range of 20 to 50 percent, fall into this category ³. The problem is that once a cancer is found, it is very hard to know which ones are the harmless kind, so many men are treated, and prostate treatment carries its own risks of incontinence and sexual dysfunction.

Even before treatment, a raised PSA sets a chain in motion: repeat tests, an MRI, sometimes a biopsy that carries a small risk of bleeding or infection, and weeks of worry threaded through all of it. This is precisely the pattern the evidence on avoiding unnecessary testing keeps flagging, that broad testing of people who feel well generates false alarms and incidental findings faster than it generates saved lives ⁴. I walked through the harms of over-testing and overdiagnosis in more detail elsewhere, because it is the half of the ledger the leaflets tend to underweight.

Turning it into a decision, not a default

The right move with PSA is a shared decision that weighs your age, your risk, and how you personally feel about a small benefit set against real harms, rather than an automatic yes or no. The long-standing principles for judging whether to screen a healthy population ask not only whether a test can find a disease, but whether finding it early actually changes the outcome for the better, a bar prostate screening only partly clears ⁵. That is why the sensible answer so often sounds like a conversation rather than a rule.

With my father, the useful thing turned out not to be a verdict but a set of questions: what would you do if it were found, how would you feel about monitoring a cancer rather than treating it, and are you the sort of person more troubled by a missed problem or by a false alarm. He talked those through with his own clinician, who knew his history in a way no leaflet or website ever could, and reached a decision that was genuinely his. That is the whole point of a shared decision, and it is the one part of this I would not want anyone to outsource.

This article is general information, not medical advice. Whether a PSA test is right for you depends on your own history and risk, and that is a conversation for a clinician who knows them.